Arsenic and arsenic containing compounds are human carcinogens. Exposure to arsenic occurs occupationally in several industries, including mining, pesticide, pharmaceutical, glass and microelectronics, as well as environmentally from both industrial and natural sources. Inhalation is the principal route of arsenic exposure in occupational settings, while ingestion of contaminated drinking water is the predominant source of significant environmental exposure globally. Drinking water contamination by arsenic remains a major public health problem. Acute and chronic arsenic exposure via drinking water has been reported in many countries of the world, where a large proportion of drinking water is contaminated with high concentrations of arsenic. General health effects that are associated with arsenic exposure include cardiovascular and peripheral vascular disease, developmental anomalies, neurologic and neurobehavioural disorders, diabetes, hearing loss, portal fibrosis, hematologic disorders (anemia, leukopenia and eosinophilia) and multiple cancers: significantly higher standardized mortality rates and cumulative mortality rates for cancers of the skin, lung, liver, urinary bladder, kidney, and colon in many areas of arsenic pollution. Although several epidemiological studies have documented the sources of exposure and the global impact of arsenic contamination, the mechanisms by which arsenic induces health effects, including cancer, are not well characterized. Further research is needed to provide a better understanding of the pathobiology of arsenic-induced diseases and to better define the toxicologic pathology of arsenic in various organ systems. In this review, we provide and discuss the underlying pathology and nature of arsenic-induced lesions. Such information is critical for understanding the magnitude of health effects associated with arsenic exposure throughout the world.
Abernathy CO , Liu YP, Longfellow D., Aposhian HV, Beck B., Fowler B., Goyer R., Menzer R., Rossman T., Thompson C., Waalkes M. (1999). Arsenic: Health effects, mechanisms of actions and research issues. Environ Health Perspect107: 593—597.
2.
Agency for Toxic Substances and Disease Registry (ATSDR) (2000). Toxicological Profile for Arsenic TP-92/09. Center for Disease Control, Atlanta, Georgia .
3.
Ahmad S., Kitchin KT, Cullen WR (2000). Arsenic species that cause release of iron from ferritin and generation of activated oxygen. Arch Biochem Biophys382: 195—202.
4.
Alemany M., Levin J. (2000). The effects of arsenic trioxide on human megakaryocyticleukemia cell lines with a comparison of its effects on other cell lineages. Leuk Lymphoma38(1—2): 153—163.
5.
Aposhian HV, Gurzau ES, Le XC, Gurzau A., Healy SM, Lu X., Ma M., Yip L., Zakharyan RA, Maiorino RM, Dart RC, Tircus MG, Gonzalez-Ramirez D., Morgan DL, Avram D., Aposhian MM (2000a). Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem Res Toxicol13(8): 693—697.
6.
Aposhian HV, Zheng B., Aposhian MM, Le XC, Cebrian ME, Cullen W., Zakharyan RA, Ma M., Dart RC, Cheng Z., Andrewes P., Yip L., O'Malley GF, Maiorino RM, Van Voorhies W., Healy SM, Titcomb A. (2000b). DMPS-arsenic challenge test II. Modulation of arsenic species, including monomethylarsonous acid (MMA (III)), excreted in human urine. Toxicol Appl Pharmacol165: 74—83.
7.
Armstrong CW , Stroube R., Rubio T. (1984). Outbreak of fatal arsenic poisoning caused by contaminated drinking water . Arch Environ Health39: 276—279.
8.
Arnold LL, Cano M., St. John M., Eldna M., Van Gemert M., Cohen SM (1999). Effects of dietary dimethylarseinic acid on the urine and urothelium of rats. Carcinogenesis20: 2171—2179.
9.
Aschengrau A. , Zierler S., Cohen A. (1989). Quality of community drinking water and the occurrence of spontaneous abortion . Arch Environ Health44: 283—290.
10.
Barchowsky A., Dudek EJ, Treadwell MD, Wetterhahn KE (1996). Arsenic induces oxidant stress and NFκB activation in cultured aortic endothelial cells. Free Radic Biol Med21: 783—790.
11.
Barrett JC, Lamb PW, Wang TC, Lee TC (1989). Mechanisms of arsenic-induced cell transformation . Biol Trace Elem Res21: 421— 429.
12.
Belton JC, Benson NC, Hanna ML, Taylor RT (1985). Growth inhibition and cytotoxic effects of three arsenic compounds on cultured Chinese hamster ovary cells. J Environ Sci Health20A: 37—72.
13.
Biggs ML, Haque R., Moore L., Smith A. (1998). Arsenic-laced water in Chile. Science281: 785.
14.
Boonchai W. , Walsh M., Cummings M., Chenevix-Trench G. (2000 ). Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch Dermatol136: 195—198.
15.
Borgono JM, Vicent P., Venturino H., Infante A. (1977). Arsenic in the drinking water of the city of Antofagasta: epidemiological and clinical study before and after the installation of a treatment plant. Environ Health Perspect19: 103—105.
16.
Borzsonyi M. , Bereczky A., Rudnai P., Csanady M., Horvath A. (1992). Epidemiological studies on human subjects exposed to arsenic in drinking water in Southwest Hungary . Arch Toxicol66: 77—78.
17.
Brown J., Kitchin KT (1996). Arsenite, but not cadmium, induces ornithine decarboxylase and heme oxygenase activity in rat liver: Relevance to arsenic carcinogenesis . Cancer Lett98: 227—231.
18.
Burleson FG , Simeonova PP, Germolec DR, Luster MI (1996). Dermatotoxic chemical stimulate of c-jun and c-fos transcription and AP-1 DNA binding in human keratinocytes . Res Commun Mol Pathol Pharmacol93: 131—148.
19.
Calderon J. , Navarro ME, Jimenez-Capdeville ME, Santos-Diaz MA, Golden A., Rodriguez-Leyva I., Borja-Aburto V., Diaz- Barriga F. (2001). Exposure to arsenic and lead and neuropsychological development in Mexican children. Environ Res85(2): 69—76.
20.
Castren K., Ranki A., Welsh JA, Vahakangas KH (1998). Infrequent p53 mutations in arsenic-related skin lesions. Oncol Res10: 475—482.
21.
Castro JA (1982). Efectos carcinogenicos, mutagenicos y teratogenicos del arsenico. Acta Bioquim Clin Latinoam16: 3—17.
22.
Cavigelli M. , Li WW, Lin A., Su B., Yoshioka K., Karin M. (1996). The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase . EMBO J15: 6269—6279.
23.
Chappell W. , Beck B., Brown K., North D., Thornton I., Chaney R., Cothern R., Cothern CR, North DW, Irgolic K., Thornton I., Tsongas T. (1997). Inorganic arsenic: A need and an opportunity to improve risk assessment. Environ Health Perspect105: 1060—1067.
24.
Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY (1996). Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol16: 504—510.
25.
Chen CJ, Chuang YC, Lin TM, Wu HY (1985). Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: High-arsenic artesian well water and cancers . Cancer Res45: 5895—5899.
26.
Chen CJ, Lin LJ (1994). Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In: Arsenic in the Environment; Part II: Human Health and Ecosystem Effects, Nriagu JO (ed). John Wiley & Sons , New York, pp 109—131.
27.
Chen NY, Ma WY, Huang C., Ding M., Dong Z. ( 2000a). Activation of PKC is required for arsenite-induced signal transduction. J Environ Pathol Toxicol Oncol19(3): 297—306.
28.
Chen CJ, Wu MM, Lee SS, Wang JD, Chen SH, Wu HY (1988). Atherogenicity and carcinogenicity of high-arsenic artesian well water: multiple risk factors and related malignant neoplasms of blackfoot disease. Atheriosclerosis8: 452—460.
29.
Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ ( 2001). Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in Northeastern Taiwan. Am J Epidemiol153(5): 411—418.
30.
Chiou Hy , Hsueh YM, Liaw KF, Horng, SF, Chiang MH, Pu YS, Lin JS, Huang CH, Chen CJ (1995). Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan . Cancer Res55: 1296—1300.
31.
Chowdhury UK , Biswas BK, Chowdhury TR, Samanta G., Mandal BK, Basu GC, Chanda CR, Lodh D., Saha SC, Mukherjee SK, Roy S., Kabir S., Quamruzzaman Q., Chakraborti D. (2000). Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect108(5): 393—397.
32.
Clarkson TW (1991). Inorganic and organometal pesticides. In: Handbook of Pesticide Toxicology, Hayes WJ Jr, Laws ER Jr (eds). Academic Press, San Diego, pp 545—552.
33.
Clayson DB, Kitchin KT (1999). Interspecies differences in response to chemical carcinogens. In: Carcinogenicity: Testing, Predicting, and Interpreting Chemical Effects, Kitchin K (ed). Marcel Dekker, New York, pp 837—880.
34.
Concha G., Vogler G., Lezeano D., Nermell B., Vahter M. (1998). Exposure to inorganic arsenic metabolites during early human development. Toxicol Sci44: 185—190.
35.
Cullen WR, McBride BC, Reglinski J. (1984). The reduction of trimethylarsine oxide to trimethylarsine by thiols: a mechanistic model for the biological reduction of arsenicals. J InorgBiochem21: 45—60, 179— 194.
36.
Deaglio S., Canella D., Baj G., Arnulfo A., Waxman S., Malavasi F. (2001). Evidence of an immunologic mechanism behind the therapeutic effects of arsenic trioxide on myeloma cells. Leuk Res25(3): 237—239.
37.
Del Razo LM, Styblo M., Thomas DJ (2000). Determination of trivalent methylated arsenic species in water, cultured rat hepatocytes, and human urine. 4th International Conference on Arsenic Exposure and Health Effects, Poster 10. San Diego, California, USA.
38.
Ellenhorn MJ , Barceloux DG (1988). Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Elsevier, New York , pp 1012—1016.
39.
Engel RE, Smith AH (1994). Arsenic in drinking water and mortality from vascular disease: an ecological analysis in 30 counties in the United States. Arch Environ Health49: 418—427.
40.
Enterline PE , Henderson VL, Marsh GM (1987). Exposure to arsenic and respiratory cancer: a reanalysis. Am J Epidemiol125: 929—938.
41.
Enterline PE , Marsh GM (1982). Cancer among workers exposed to arsenic and other substances in a copper smelter. Am J Epidemiol116: 895— 911.
42.
Ferreccio C. , Gonzalez C., Milosavlijevic V., Marshall G., Sancha AM (1998). Lung cancer and arsenic exposure in drinking water: a case control study in Northern Chile. Cad Saude Publica14: 193—198.
43.
Ferreccio C. , Gonzalez C., Milosavlijevic V., Marshall G., Sancha AM, Smith AH (2000). Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology11(6): 673—679.
Gerhardsson L., Brune D., Nordberg GF, Wester PO (1988). Multielemental assay of tissues of deceased smelter workers and controls. Sci Total Environ74: 97—110.
46.
Gerhardt RE , Hudson JB, Rao RN, Sobel RE (1978). Chronic renal insufficiency from cortical necrosis induced by arsenic poisoning . Arch Intern Med138: 1267—1269.
47.
Germolec DR , Spalding T., Boorman GA, Wilmer JL, Yoshida T., Simeonova PD, Bruccoleri A., Kayama F., Gaido K., Tennant R., Burleson F., Dong W., Lang RW, Luster MI (1997). Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res386: 209—218.
48.
Giberson A. , Vaziri ND, Mirahamadi K., Rosen SM (1976). Hemodialysis of acute arsenic intoxication with transient renal failure. Arch Intern Med136: 1303—1304.
49.
Gonsebatt ME , Vega L., Salazar AM, Montero R., Guzman P., Blas J., Del Razo LM, Garcia-Vargas G., Albores A., Cebrian ME, Kelsh M., Ostrosky-Wegman P. (1997 ). Cytogenetic effects in human exposure to arsenic. Mutat Res386: 219—298.
50.
Gorby MS (1988). Arsenic poisoning. West J Med149: 308—315.
51.
Goyer RA (1996). Toxic effects of metals. In: Cassarett & Doull's Toxicology—The Basic Science of Poisons, Klaassen CD (ed). McGraw Hill, New York, pp 691—736.
52.
Greenblatt MS, Bennett WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res54: 4855—4878.
53.
Gurr J., Liu F., Lynn S., Jan K. (1998). Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. Mutat Res416: 137— 148.
54.
Hamadeh HK, Vargas M., Lee E., Menzel DB (1999). Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem Biophys Res Commun263(2): 446—449.
55.
Hanahan D., Weinberg RA (2000). The hallmarks of cancer. Cell100: 57—70.
56.
Harris CC (1996). p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment . Environ Health Perspect104(suppl 3): 435—439.
57.
Hartmann A. , Speit G. (1994). Comparative investigations of the Genotoxic effects of metals in the single cell gel assay and the sister-chromatid exchange test. Environ Mol Mutagen23: 299—305.
58.
Hartwig A., Groblinghoff UD, Beyersmann D., Natarajan AT, Filon R., Mullenders LHF (1997). Interaction of Arsenic (III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis18: 399— 405.
59.
Hazardous Chemicals Data (HAZDAT) (1992). Agency for Toxic Substances and Disease Registry. Atlanta, Georgia.
60.
Hernandez-Zavala A., Del Razo LM, Aguilar C., Garcia-Vargas GG, Borja VH, Cebrian ME (1998). Alteration in bilirubin excretion in individuals chronically exposed to arsenic in Mexico. Toxicol Lett99(2): 79—84.
61.
Hernandez-Zavala A., Del Razo LM, Garcia-Vargas GG, Aguilar C., Borja VHAlbores A., Cebrian ME (1999). Altered activity of heme biosynthesis pathway enzymes in individuals chronically exposed to arsenic in Mexico. Arch Toxicol73(2): 90—95.
62.
Hindmarsh JT , McCurdy RF (1986). Clinical and environmental aspects of arsenic toxicity. CRC Crit Rev Clin Lab Sci23: 315—347.
63.
Hopenhayn-Rich C., Biggs ML, Fuchs A., Bergoglio R., Tello EE, Nicolli H., Smith AH (1996). Bladder cancer mortality associated with arsenic in drinking water in Argentina . Epidemiology7: 117—124.
64.
Hopenhayn-Rich C., Biggs ML, Smith A. (1998). H. Lung andkidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina . Int J Epidemiol27: 561—569.
65.
Hsu CH, Yang SA, Wang JY, Lin SR (1999). Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer80: 1080—1086.
66.
Hsueh YM, Wu WL, Huang YL, Chiou HY, Tseng CH, Chen CJ ( 1998). Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis141: 249— 257.
67.
Hu Y., Su L., Snow ET ( 1998). Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition on DNA repair enzymes. Mutat Res408: 203—218.
68.
Huang SC, Lee TC (1998). Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogenesis19: 889—896.
69.
Hutchinson J. (1887a). Arsenic cancer. Br Med J2: 1280—1281.
70.
Hutchinson J. (1887b). On some examples of arsenic-keratosis of the skin and of arsenic-cancer. Trans Pathol Soc Lond39: 352—363.
71.
Ihrig MM, Shalat SL, Baynes C. (1998). A hospital-based case-control study of stillbirths and environmental exposure to arsenic using an atmospheric dispersion model linked to a geographical information system. Epidemiology9: 290—294.
72.
Jacobson Kram D., Montalbano D. (1985). The reproductive effects assessment group's report on the mutagenicity of inorganic arsenic . Environ Mutagen7: 789—804.
73.
Jha AN, Noditi M., Nilsson R., Natarajan AT (1992). Genotoxic effects of sodium arsenite on human cells. Mutat Res284: 215—221.
74.
Kaltreider RC, Davis AM, Lariviere JP, Hamilton JW (2001). Arsenic alters the function of the glucocorticoid receptor as a transcription factor. Environ Health Perspect109(3): 245—251.
75.
Kitchin KT (2001). Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol172: 249—261.
76.
Kosnett MJ (1994). Arsenic. In: Poisoning and Drug Overdose, Olson KK (ed). Appleton & Lange, Norwalk, Connecticut, pp 87—89.
77.
Kuo TT, Hu S., Lo SK, Chan HL ( 1997). p53 expression and proliferative activity in Bowen's disease with or without chronic arsenic exposure. Hum Pathol28(7): 786—790.
78.
Lai MS, Hsueh YM, Chen CJ, Shyu MP, Chen SY, Kuo TL, Wu MM, Tai TY (1994). Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol139: 484—492.
79.
Landolph JR (1989). Molecular and cellular mechanisms of transformation of C3H/10T1/2C18 and diploid human fibroblasts by unique carcinogenic, nonmutagenic metal compounds. A review. Biol Trace Elem Res21: 459— 467.
80.
Lane DP, Benchimol S. (1990). p53: oncogene or anti-oncogene. Genes Dev4: 1—8.
81.
Le XC, Lu X., Ma M., Cullen WR, Aposhian HV, Zheng B. (2000). Speciation of key arsenic metabolic intermediates in human urine. Anal Chem72: 5172—5177.
82.
Lee TC, Oshimura M., Barrett JC (1985). Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis6(10): 1421—1426.
83.
Lee TC, Tanaka N., Lamb PW, Gilmer TM, Barrett JC (1988). Induction of gene amplification by arsenic. Science241: 79—81.
84.
Lee-Feldstein A. (1983). Arsenic and respiratory cancer in man: follow-up of an occupational study. In: Arsenic: Industrial, Biomedical, and Environmental Perspectives, Lederer W, Fensterheim R (eds). Van Nostrand-Reinhold, New York, pp 245—254.
85.
Lee-Feldstein A. (1986). Cumulative exposure to arsenic and its relationship to respiratory cancer among copper smelter employee . J Occup Med28: 296—302.
86.
Levin AJ, Momand J., Finlay CA (1991). The p53 tumor suppressor gene. Nature. 351: 453—456.
87.
Lewis DR, Southwick JW, Oullet-Hellstrom R., Rench J., Calderon RL (1999). Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect107: 359—365.
88.
Li JH, Rossman TC (1989). Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. MolToxicol2: 1—9.
89.
Lin S., Cullen WR, Thomas DJ (1999). Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol12: 924—930.
90.
Liu J., Kadiiska M., Liu Y., Qu W., Mason RP, Waalkes MP (2000). Acute arsenic-induced free radical production and oxidative stress-related gene expression in mice. Toxicologist54: 280—281.
91.
Lu T., Liu J., LeCluyse EL, Zhou YS, Cheng ML, Waalkes MP (2001). Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci59(1): 185—192.
92.
LuchtrathH. (1983). The consequences of chronic arsenic poisoning among Moselle wine growers: pathoanatomical investigations of post-mortem examinations performed between 1960 and 1977. J Cancer Res Clin Oncol105: 173—182.
93.
Madal BK, Chowdhury TR, Samanta G., Basu GK, Chowdhury PP, Chanda CR, Lodh D., Karan NK, Dhar RK, Tamili DK (1996). Arsenic in groundwater in seven districts of West Bengal, India: the biggest arsenic calamity in the world. Curr Sci70: 976—986.
94.
Mahata J., Basu A., Ghoshal S., Sarkar JN, Roy AK, Poddar G., Nandy AK, Banerjee A., Ray K., Natarajan AT, Nilsson R., Giri AK ( 2003). Chromosomal aberrations and sister-chromatid exchanges in individuals exposed to arsenic through drinking water in West Bengal, India . Mutat Res534: 133—143.
95.
Marafante E. , Vahter M. (1987). Solubility, retention, and metabolism of intratracheally and orally administered inorganic arsenic compounds in the hamster. Environ Res42: 72—82.
96.
Mass MJ, Tennant A., Roop B., Kundu K., Brock K., Kligerman A., Demarini D., Wang C., Cullen W., Thomas D., Styblo M. (2001). Methylated arsenic (III) species react directly with DNA and are potential proximate or ultimate genotoxic forms of arsenic . Toxicologist60: 358.
97.
Mass MJ, Wang L. ( 1997). Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res386: 263—277.
98.
Matsui M., Nishigori C., Toyokuni S., Takada J., Mitsuhiko A., Ishikawa M., Imamura S., Miyachi Y. (1999). The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2'-deoxyguanosine in arsenic-related Bowen's disease. J Invest Dermatol113: 26—31.
99.
Mazumder G. , Chakraborty A., Ghose A., Gupta JD, Dey SD, Chattopadhyay N. (1988). Chronic arsenic toxicity from drinking tubewell water in rural West Bengal . Bull WHO66: 499—506.
100.
Mazumder Guha DN, Gupta Das J., Santra A. (1997). Non-cancer effects of chronic arsenicosis with special reference to liver damage. In: Arsenic Exposure and Health Effects, Abernathy C, Calderon RL , Chappel WR (eds). Chapman and Hall, London, pp 112—123.
101.
Mazumder DN , Haque R., Ghosh N., De BK, Santra A., Chakraborty D., Smith A. (1998). Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int J Epidemiol27: 871—877.
102.
Mazumder DN , Haque R., Ghosh N., De BK, Santra A., Chakraborti D., Smith AH (2000). Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. Int J Epidemiol29(6): 1047— 1052.
103.
Milton AH, Hasan Z., Rahman A., Rahman M. (2001). Chronic arsenic poisoning and respiratory effects in Bangladesh. J Occup Health43(3): 136—140.
104.
Moolgavkar SH (1986). Carcinogenesis modeling: from molecular biology to epidemiology. Annu Rev Public Health7: 151—169.
105.
Morton WE, Dunnette DA (1994). Health effects of environmental arsenic. In: Arsenic in the Environment Part II; Human Health and Ecosystem Effects, Nriagu JO (ed). John Wiley & Sons, Inc, New York, pp 17—34.
106.
Murgo AJ (2001). Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist6(suppl 2): 22—28.
107.
Nakamuro K. , Sayato Y. (1981). Comparative studies of chromosomal aberration induced by trivalent and pentavalent arsenic . Mutat Res88: 73—80.
108.
Natarajan AT, Boei JJ, Darroudi F., Van Diemen PC, Doulout F., Hande MP and Ramalho AT (1996). Current cytogenetic methods for detecting exposure and effects of mutagens and carcinogens. Environ Health Perspect104(Suppl.3): 455—458.
109.
National Academy of Science ( 1977). Arsenic. Author, Washington, DC.
110.
National Institutes of Health (NIH) (1999). National Toxicology Program's Technical Report on the Toxicology and Carcinogenesis Studies of Gallium Arsenide in F344/N Rats and B6C3F1 Mice. NTPTR 492. NIH publication No. 99-3951. Bethesda, Maryland, USA.
111.
National Research Council ( 1994). Science and Judgement in Risk Assessment. Assessment of Toxicology, National Academy of Sciences (eds). National Academy Press, Washington, DC, pp 56—67.
112.
NRC (National Research Council) (1999). Arsenic in Drinking Water. Author, Washington, DC.
113.
NRC (National Research Council) (2001). Arsenic in Drinking Water: Update. National Academy Press, Washington, DC.
114.
Nordstrom S., Beckman L., Nordenson I. (1978a). Occupational and environmental risk in and around a smelter in northern Sweden. I: variations in birth weight . Hereditas88: 43—46.
115.
Nordstrom S., Beckman L., Nordenson I. (1978b). Occupational and environmental risk in and around a smelter in northern Sweden. III: frequencies of spontaneous abortion. Hereditas88: 51—54.
116.
Nordstrom S., Beckman L., Nordenson I. (1979a). Occupational and environmental risk in and around a smelter in northern Sweden. V: spontaneous abortion among female employees and decreased birth weight in their offspring. Hereditas90: 291—296.
117.
Nordstrom S., Beckman L., Nordenson I. (1979b). Occupational and environmental risk in and around a smelter in northern Sweden. VI: congential malformations . Hereditas90: 297—302.
118.
Paigen B., Goldman LR, Magnant MM, Highland JH, Steegmann Jr, AT (1987). Growth of children living near the hazardous waste site, Love canal. Human Biol59: 489—508.
119.
Parrish AR , Zheng XH, Turney KD, Younis HS, Gandolfi AJ (1999). Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol Sci50(1): 98—105.
120.
Petrick JS, Ayala-Fierro F., Cullen WR, Carter DE, Aposhian HV (2000). Monomethylarsonous acid (MMAIII) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol163: 203—207.
121.
Popovicova J. , Moser GJ, Goldsworthy TL, Tice RR (2000). Carcinogenicity and co-carcinogenicity of sodium arsenite in p53+/− male mice. Toxicologist54: 134.
122.
Porter AC, Fanger GR, Vaillancourt RR (1999). Signal transduction pathways regulated by arsenate and arsenite. Oncogene18(54): 7794— 7802.
123.
Puccetti ES, Guller S., Orleth A., Bruggenolte N., Hoelzer D., Ottmann OG, Ruthardt M. (2000). BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res60(13): 3409—3413.
124.
Rahman M., Axelson O. (1995). Diabetes mellitus and arsenic exposure: a second look at case-control data from a Swedish copper smelter. Occup Environ Med52: 773—774.
125.
Rahman M., Tondel M., Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. (1999). Hypertension and arsenic exposure in Bangladesh . Hypertension. 33(1): 74—78.
126.
Rahman M., Wingren G., Axelson O. (1996). Diabetes mellitus among Swedish art glassworkers- an effect of arsenic exposure. Scand J Work Environ Health22: 146—149.
127.
Ramirez P. , Eastmond DA, Laclette JP, Ostrosky-Wegman P. (1997 ). Disruption of microtubule assembly and spindle formation for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide . Mutat Res386: 291—298.
128.
Rousselot P., Laboume S., Marolleau JP, Larghero T., Noguera ML, Brouet JC, Fermand JP (1999). Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in Plasma cells from myeloma patients. Cancer Res59: 1041—1048.
129.
Salazar AM , Ostrosky-Wegman P., Menendez D., Miranda E., Garcia-Carranca A., Rojas E. (1997). Induction of p53 protein expression by sodium arsenite. Mutat Res381: 259—265.
130.
Sampayo-Reyes A., Zakharyan RA, Healy SH, Aposhian HV (2000). Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue . Chem Res Toxicol13: 1181—1186.
131.
Santra A., Gupta Das J., De BK, Roy B. and Mazumder DN (1999). Hepatic manifestations in chronic arsenic toxicity . Indian J Gastroenterol18(4): 152—155.
132.
Schaumloffel N., Gebel T. (1998). Heterogeneity of the DNA damage provoked by antimony and arsenic. Mutagenesis13: 281—286.
133.
Schoolmaster WL, White DR (1980). Arsenic poisoning . South Med J73: 198—208.
134.
Schwartz J. , Angle C., Pitcher H. (1986). Relationship between childhood blood lead level and stature. Pediatrics77: 281—288.
135.
Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, Lee YY (1999). Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell-line PCI-1. Biochem Biophys Res Commun265(2): 400—404.
136.
Simeonova PP, Luster MI (2000). Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms?J Environ Pathol Toxicol Oncol19: 281—286.
137.
Simeonova PP, Wang S., Toriumi W., Kommineni C., Matheson J., Unimye N., Kayama F., Harki D., Ding M., Vallyathan V., Luster MT (2000). Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with AP-1 transactivation. Cancer Res60: 3445—3453.
138.
Siripitayakunkit U., Visudhiphan P., Pradipasen M., Vorapongsathon T. (1999). Association between chronic arsenic exposure and children's intelligence in Thailand. In: Arsenic Exposure and Health effects, Chappell, WR, Abernathy CO , Calderon RL (eds). Elsevier, New York, pp 141—150.
139.
Smith AH, Goycolea M., Haque R., Biggs ML (1998). Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol147: 660—669.
140.
Soignet S., Calleja E., Cheung NK, Pezzulli S., Vongphrachanh P., Spriggs D., Warrell RP (1999). A Phase 1 study of arsenic trioxide in patients with solid tumors, Memorial Sloan-Kettering Cancer Center, New York, NY. Program/Proceedings Abstracts for 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, May 15—18, Vol. 18.
141.
Squibb KS, Fowler BA (1983). The toxicity of arsenic and its compounds. In: Biological and Environmental Effects of Arsenic, Fowler BA (ed). Elsevier, New York, pp 233—269.
142.
Styblo M., Del Razo LM, LeCluyse EL, Hamilton GA, Wang C., Cullen WR, Thomas DJ (1999). Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol12: 560—565.
143.
Styblo M., Hughes MF, Thomas DJ (1996). Liberation and analysis of protein-bound arsenicals . J Chromatogr B 677: 161—166.
144.
Styblo M., Serves SV, Cullen WR, Thomas DJ (1997). Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem Res Toxicol10: 27—33.
145.
Styblo M., Yamauchi H., Thomas DJ (1995). Comparative in vitro methylation of trivalent and pentavalent arsenicals. Toxicol Appl Pharmacol135: 172—178.
146.
Takahashi M., Barrett JC, Tsutsui T. (2002). Transformation by inorganic arsenic compounds of normal Syrian hamster embryo cells into aneoplastic state in which they become anchorage-independent and cause tumors in newborn hamsters . Int J Cancer99: 629—634.
147.
Tchounwou PB, Wilson B., Ishaque A. (1999). Important considerations in the development of public health advisories for arsenic and arsenic-containing Compounds in drinking water. Rev Environ Health14(4): 211— 229.
Thompson DJ (1993). A chemical hypothesis for arsenic methylation in mammals. Chem-Biol Interact88: 89—114.
150.
Tokudome S. , Kuratsune M. (1976). A cohort study on mortality from cancer and other causes among workers at a metal refinery . Int J Cancer17: 310— 317.
151.
Trouba KJ, Wauson EM, Vorce RL (2000). Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol Appl Pharmacol164(2): 161—170.
152.
Tsai S., Wang T., Ko Y. (1999). Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch EnivronHealth54: 186—193.
153.
Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, Chiou HY, Hsueh YM, Hsu KH, Chen CJ ( 2000). Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: A cohort study in arseniasis-hyperendemic villages in Taiwan . Environ Health Perspect108 (9): 847—851.
154.
Tseng WP (1989). Blackfoot disease in Taiwan: a 30-year follow-up study. Angiology40: 547—558.
155.
Tsuda T., Nagira T., Yamamoto M. (1990). An epidemiological study on cancer in certified arsenic poisoning patients in Toroku. Ind Health28: 53—62.
156.
Tucker SB, Lamm SH, Li FX, Wilson R., Byrd DM, Lai S., Tong Y., Loo L. (2001). Relationship between Consumption of Arsenic-Contaminated Well Water and Skin Disorders in Huhhot, Inner Mongolia. Inner Mongolia Cooperative Arsenic Project (IMCAP) study. Final Report. Dept. of Dermatology, University of Texas, Houston, and Dept. of Environmental Epidemiology, Institute of Environmental Engineering, Chinese Academy of Preventive Medicine, Beijing, China.
157.
Tully DB, Collins BJ, Overstreet JD, Smith CS, Dinse GE, Mumtaz MM, Chapin RE (2000). Effects of arsenic, cadmium, chromium and lead on gene expression regulated by a battery of 13 different promoters in recombinant HepG2 cells. Toxicol Appl Pharmacol168(2): 79—90.
158.
Vahter ME (1988). Arsenic. In: Biological Monitoring of Toxic Metals, Clarkson TW, Friberg L, Nordberg GF, SagerPR (eds). Plenum, New York, pp 303—321.
159.
Vega L., Gonsebatt ME, Ostrosky-Wegman P. (1995). Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat Res334(3): 365—373.
160.
Vega L., Styblo M., Patterson R., Cullen W., Wang C., Germolec D. (2001). Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol172(3): 225—232.
161.
Venugopal B., Lucky TD (1978). Metal Toxicity in Mammals. Plenum Press, New York.
162.
Vogt BL, Rossman TG (2001). Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts—a possible mechanism for arsenite's comutagenicity . Mutat Res478(1—2): 159—168.
163.
Wall S. (1980). Survival and mortality pattern among Swedish smelter workers. Int J Epidemiol9: 73—87.
164.
Wang Z., Rossman TG (1996). In: The Toxicology of Metals, vol 1, Cheng LW (ed). CRC Press, Boca Raton, Florida, pp 221—243.
165.
Wanibuchi H. , Hori T., Meenakshi V., Ichihara T., Yamamoto S., Yano Y., Otani S., Nakae D., Konishi Y., Fukushima S. (1997). Promotion of rat hepatocarcinogenesis by dimethylarsinic acid as assessed in rat in vivo models: a review. Mutat Res386: 353—361.
166.
Warner ML, Moore LE, Smith MT, Kalman DA, Fanning E., Smith AH (1994). Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada . Cancer Epid Biomarker Prevent3: 583—590.
167.
Wei M., Wanibuchi H., Morimura K., Iwai S., Yoshida K., Endo G., Nakae D., Fukushima S. (2002). Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis23(8): 1387—1397.
168.
Winship KA (1984). Toxicity of inorganic arsenic salts. Adv Drug ReactAcute Poisoning Rev3: 129—160.
169.
Wu MM, Kuo TL, Hwang YH, Chen CJ ( 1989). Dose-response relationship between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epid130: 1123—1132.
170.
Yamamoto S. , Konishi Y., Matsuda T., Murai T., Shibata M., Matsui-Yuasa I., Otani S., Kuroda K., Endo G., Fukushima S. (1995). Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens . Cancer Res55: 1271—1275.
171.
Yamanaka K. , Hoshino M., Okanoto M., Sawamura R., Hasegawa A., Okada S. (1990). Induction of DNA damage by dimethylarsine a metabolite of inorganic arsenics, is for the major part likely due to its peroxyl radical. Biochem Biophys Res Commun168: 58—64.
172.
Yamanaka K. , Mizoi M., Kato K., Hasegawa A., Nakano M., Okada S. (2001). Oral administration of dimethylarsinic acid, a main metabolite of inorganic arsenics, promote skin tumorigenesis in mice. Biol Pharm Bull24: 510—514.
173.
Yamashita N., Doi M., Nishio M., Hojo H., Tanaka M. (1972). Recent observations of Kyoto children poisoned by arsenic tainted “Morinaga Dry Milk.” JpnJ Hyg27: 364—399.
174.
Zakharyan RA, Ayala-Fierro F., Cullen WR, Carter DM, Aposhian HV (1999). Enzymatic methylation of arsenic compounds VII. Monomethylarsonous acid (MMAIII) is the substrate for MMA methyltransferase of rabbit liver and human hepatocytes . Toxicol Appl Pharmacol158: 9—15.
175.
Zakharyan RA, Aposhian HV (1999). Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMAV reductase. Chem Res Toxicol12: 1278—1283.
176.
Zaldivar R. (1980). A morbid condition involving cardiovascular, bronchopulmonary, digestive and neural lesions in children and young adults after dietary arsenic exposure. Zentralbl Bakteriol170: 44— 56.
177.
Zaldivar R. , Ghai GL (1980). Clinical epidemiological studies on endemic chronic arsenic poisoning in children and adults, including observations on children with high and low-intake of dietary arsenic. 1. Zentralbl Bakteriol. Abt Originale B: Hygiene, Krankenhaushygiene, Betriebshygiene, Praventive Medizin170: 409—421.
178.
Zelikoff JT , Bertin JE, Burbacher TM, Hunter ES, Miller RK, Silbergeld EK, Tabacova S., Rogers JM (1995). Health risks associated with prenatal metal exposure. Fundam Appl Toxicol25: 161—170.
179.
Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP (1997). Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA94: 10907— 10912.
180.
Zhong CX, Wang L., Mass MJ ( 2001). Differentially methylated DNA sequences associated with exposure to arsenate in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol Lett122(3): 223—234.
181.
Zierler S. , Theodore M., Cohen A., Rothman KJ (1988). Chemical quality of maternal drinking water and congenital heart disease. Int J Epidemiol17: 589—594.
